Royce & Associates’s Aerie Pharmaceuticals AERI Stock Holding History

Royce & Associates’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-22,300	Closed	-$203K	–	1002
2022 Q1	$203K	Hold	22,300	–	–	﹤0.01%	943
2021 Q4	$157K	Hold	22,300	–	–	﹤0.01%	951
2021 Q3	$254K	Hold	22,300	–	–	﹤0.01%	956
2021 Q2	$357K	Sell	22,300 -95,350	-81%	-$1.64M	﹤0.01%	957
2021 Q1	$2.1M	Buy	+117,650	New	+$2.03M	0.01%	749
2015 Q3	–	Sell	-86,000	Closed	-$1.52M	–	1232
2015 Q2	$1.52M	Hold	86,000	–	–	0.01%	973
2015 Q1	$2.69M	Sell	86,000 -57,000	-40%	-$1.65M	0.01%	881
2014 Q4	$4.17M	Buy	143,000 +43,000	+43%	+$1.09M	0.01%	820
2014 Q3	$2.07M	Buy	+100,000	New	+$1.97M	0.01%	1001

Other funds holding AERI

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Royce & Associates's AERI Position: Q2 2022 in Review

Royce & Associates sold out of Aerie Pharmaceuticals (AERI) in Q2 2022, closing a stake of 22,300 shares — an estimated $203K sold.

Royce & Associates first reported a position in AERI in Q3 2014 and held it in 9 quarters. The position peaked at $4.17M in Q4 2014. 137 funds tracked by Wall St. Rank hold AERI as of Q2 2022.

Royce & Associates reported no remaining Aerie Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Royce & Associates sold 22,300 Aerie Pharmaceuticals shares in Q2 2022, an estimated $203K.
Royce & Associates first reported a position in Aerie Pharmaceuticals in Q3 2014 and held it in 9 quarters.
Royce & Associates's Aerie Pharmaceuticals position peaked at $4.17M in Q4 2014.
137 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2022.

Based on Royce & Associates's 13F filing for Q2 2022, filed 4 Aug 2022.